InvestorsHub Logo
Followers 38
Posts 6888
Boards Moderated 1
Alias Born 09/06/2014

Re: guardiangel post# 25753

Wednesday, 10/22/2014 6:10:43 PM

Wednesday, October 22, 2014 6:10:43 PM

Post# of 30046
Provista has no LC test and no plans for one.

http://provistadx.com/provistaDx-News-2014.html

Quoting that article without the third paragraph below is taking it out of context, which leads to misunderstanding. Read it again -- it's a brief history of the company:

"Launched in 2004 as Provista Life Sciences, the company initially positioned itself as a mezzanine developer of molecular diagnostics that aimed to acquire early stage biomarker tests, advance them to the clinical stage, and then sell them.

In this manner it developed a diagnostics pipeline covering a number of disease areas including Alzheimer's, Parkinson's, ovarian cancer, and lung cancer. It also developed its original breast cancer test, called the BT Test, that it sold in Ireland and the UK through International Health Technology.

Upon becoming CEO in 2011, Reese refocused the company on women's cancers and began the process of revamping its breast cancer program. In January 2013, Provista launched a 350-patient prospective trial for its breast cancer early detection test, now called DtectDx Breast. That trial is evaluating the test in women under 50 years of age."

Let me paraphrase.

Paragraph 1: Provista started in 2004.
Paragraph 2: Provista worked on Alzheimer's, Parkinson's, ovarian cancer, and lung cancer.
Paragraph 3: Resse took over in 2003 and refocused on women's cancers.

This is not complicated. Provista is not working on lung cancer, Alzheimer's, or Parkinson's now. They are working on women's cancers. Their pipeline on their website proves this.

No lung cancer. No Radient. No DR-70. Anyone who doubts this needs to contact Provista and clear up their misconception.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.